ReviewFrontiers in immunology2026
TLR7 and TLR9 have overlapping but distinct roles in systemic lupus erythematosus and Sjögren's disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Endosomal toll-like receptors (TLRs), such as TLR7 and TLR9, are key mediators of autoimmunity. Systemic lupus erythematosus (SLE or lupus) and SjD are distinct diseases that are both characterized by heightened activation of TLR7 and TLR9 signaling networks that serve as potent modulators of chronic inflammation. This review will provide an overview of the role of these receptors in lupus and SjD, with a focus on recent mechanistic insights in the field. We will compare and contrast the roles of TLR7 and TLR9 in lupus and SjD, with a focus on the importance of B cell activation in disease. Moreover, we will discuss differences observed in sex-biased organ-specific disease manifestations. Finally, we will review current and emerging therapies that target endosomal TLR pathways and discuss their utility for treatment of SLE and SjD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.